Aptorum Group Ltd - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
APM Nasdaq 2834 http://www.aptorumgroup.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aptorum Group Ltd

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022 - May 17th, 2022 12:13 pm
Here's Why We're Watching Aptorum Group's (NASDAQ:APM) Cash Burn Situation - May 9th, 2022 3:41 pm
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma - May 2nd, 2022 12:00 pm
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update - Apr 29th, 2022 8:00 pm
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted - Apr 25th, 2022 1:30 pm
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® - Apr 22nd, 2022 12:00 pm
Andean Precious Metals Announces RSU Grant - Apr 6th, 2022 11:00 am
Is Andean Precious Metals Corp.'s (CVE:APM) 4.2% ROE Worse Than Average? - Mar 22nd, 2022 9:58 pm
Andean Precious Metals Reports 2021 Earnings; Delivers on Silver Production and Cost Guidance - Mar 17th, 2022 11:00 am
SDC Stock Alert: What Has SmileDirectClub Investors Grinning Ear to Ear Today - Jan 25th, 2022 3:06 pm
APM Stock Alert: What Is Going on With Little-Known Aptorum Today? - Jan 25th, 2022 1:21 pm
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - Jan 25th, 2022 12:45 pm
Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer - Jan 20th, 2022 1:47 pm
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma - Jan 20th, 2022 1:00 pm
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma - Jan 18th, 2022 1:00 pm
Aptorum Group (NASDAQ:APM) investors are sitting on a loss of 90% if they invested three years ago - Jan 11th, 2022 9:56 am
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers - Jan 10th, 2022 1:00 pm
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology - Jan 10th, 2022 1:00 pm
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma - Jan 10th, 2022 1:00 pm
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders - Dec 3rd, 2021 1:00 pm